Compare Nova Ltd (NVMI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nova Ltd vs GeneDx Holdings Corp — how do they compare? Nova Ltd trades at $375.04 (market cap $11.99B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Nova Ltd is far larger — about 4.7× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| NVMI | WGS | |
|---|---|---|
Market Cap | $11.99B | $2.56B |
Sector | Technology | Technology |
52-Week High | $605.65 | $167.51 |
52-Week Low | $275.78 | $34.51 |
Enterprise Value | $11.78B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
